Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients
Status:
NOT_YET_RECRUITING
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This study aims to investigate the potential improvement in muscle function, compared to the placebo group, through the concurrent administration of denosumab and alfacalcidol over a one-year period in postmenopausal women with functional sarcopenia and osteoporosis aged 65 and older. The study is planned as a double-blinded randomized controlled trial, intending to recruit a total of 340 participants. Primary outcome is the improvement in SPPB score of 0.5 or more compared to the control group.